GSK WO2011025799

http://www.google.com/patents/WO2011025799A1?cl=en


Example 72
7V-[(3S)-l-(3-cyano-4'-fluoro-4-biphenylyl)-3-pyrrolidinyl]-L-prolinami(ie
hydrochloride

A solution of 1,1-dimethylethyl (25)-2-({[(35)-l-(3-cyano-4'-fluoro-4-biphenylyl)- 3-pyrrolidinyl]amino}carbonyl)-l-pyrrolidinecarboxylate (72 mg, 0.150 mmol) in HCl (4 M solution in 1,4-dioxane, 0.50 mL, 2.00 mmol) was stirred at RT for 1 h 25 min. The reaction mixture was diluted with Et₂O (2 mL), and the resultant precipitate was filtered through a plug of cotton and washed with Et₂O (1 mL). The solid was dissolved in MeOH and concentrated under a stream of nitrogen at 50 ⁰C. Water (2 mL) was added and the mixture was lyophilized with a Genevac^® HT-4X to afford the title compound (48 mg, 77%). LC-MS m/z 379 (M+H)⁺, 0.95 min (ret time).














DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

Join me on Facebook FACEBOOK

Join me on twitter     

Join me on google plus Googleplus

 amcrasto@gmail.com

vietnam

.


 



 
 

 
 

 

 dalat city
hanoi